Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2163

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2163
---
 expect
that we will continue to incur substantial research and development and other expenses in order to discover, develop and market additional
potential products.

We
expect to continue to incur significant losses for the foreseeable future, and we anticipate that our expenses will increase substantially
if, and as, we:

    ●
    advance
    the development of our current product candidates (OCX-253, OCX-410, OCX-909, OCF-203, ODA-570, ODA-611, and ODA-579) through preclinical
    and clinical development, and, if successful, later-stage clinical trials;

    ●
    identify,
    in-license, invest in, or discover and develop new product candidates;

    ●
    advance
    our preclinical development programs into clinical development;

    ●
    experience
    delays or interruptions with our preclinical studies or clinical trials, our receipt of services from our third-party service providers
    on whom we rely, our supply chain or other regulatory challenges, including those due to unforeseen
    global events;

    ●
    seek
    regulatory approvals for any product candidates that successfully complete clinical trials;

    ●
    commercialize
    any one or more of our product candidates and any future product candidates, if approved;

    ●
    increase
    the amount of research and development activities to identify and develop product candidates;

    ●
    hire
    additional clinical development, quality control, scientific and management personnel, including personnel to support our clinical
    development and manufacturing efforts and our operations as a public company;

    ●
    expand
    our operational, financial and management systems and establish office, research and manufacturing space;

    ●
    establish
    a business development, partnering, sales, marketing, medical affairs and/or distribution infrastructure to commercialize any products
    for which we may obtain marketing approval and intend to commercialize on our own or jointly with third parties; and

    ●
    maintain,
    expand and protect our intellectual property portfolio.

68

To
become and remain profitable, we must develop and eventually commercialize products with significant market potential. This will require
us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials, obtaining marketing
approval for product candidates, manufacturing, marketing and selling products for which we may obtain marketing approval and satisfying
any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we